福安药业
(300194)
| 流通市值：40.46亿 | | | 总市值：49.73亿 |
| 流通股本：9.68亿 | | | 总股本：11.90亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 809,399,726.88 | 2,647,752,954.05 | 1,982,986,710.24 | 1,328,520,414.35 |
| 营业收入 | 809,399,726.88 | 2,647,752,954.05 | 1,982,986,710.24 | 1,328,520,414.35 |
| 二、营业总成本 | 701,895,237.81 | 2,458,359,578.99 | 1,789,752,525.69 | 1,202,723,859.59 |
| 营业成本 | 396,374,807.3 | 1,234,788,737.8 | 878,595,166.66 | 574,954,642.04 |
| 税金及附加 | 8,764,290.77 | 27,648,720.37 | 19,717,062.14 | 11,858,287.55 |
| 销售费用 | 208,270,164.56 | 807,118,936.25 | 623,305,016.13 | 442,185,826.34 |
| 管理费用 | 56,115,900.53 | 242,299,957.66 | 171,869,649.97 | 110,966,004.7 |
| 研发费用 | 33,126,226.52 | 148,786,748.22 | 98,871,009.5 | 63,173,987.94 |
| 财务费用 | -756,151.87 | -2,283,521.31 | -2,605,378.71 | -414,888.98 |
| 其中:利息费用 | 7,333,407.55 | 29,565,014.62 | 21,599,573.44 | 14,322,732.55 |
| 其中:利息收入 | 8,020,807.6 | 32,015,299.98 | 24,332,089.67 | 14,825,915.11 |
| 加:公允价值变动收益 | - | 408,339.51 | 322,240.93 | 238,727.42 |
| 加:投资收益 | 25,408,721.77 | 77,393,502.73 | 56,757,154.41 | 34,536,624.55 |
| 资产处置收益 | 124,599.98 | 220,653,129.81 | 2,884,280.76 | 3,304,055.05 |
| 资产减值损失(新) | -805,141.74 | -243,559,336.28 | -6,933,227.82 | -3,938,853.93 |
| 信用减值损失(新) | -1,136,558.16 | 1,892,149.03 | -2,793,555.91 | -334,846.3 |
| 其他收益 | 15,602,476.83 | 52,308,210.92 | 37,974,221.63 | 25,167,372.87 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 146,698,587.75 | 298,489,370.78 | 281,445,298.55 | 184,769,634.42 |
| 加:营业外收入 | 1,081,891.85 | 1,557,905.02 | 870,088.95 | 722,599.33 |
| 减:营业外支出 | 4,551,417.97 | 9,689,486.16 | 5,710,588.97 | 4,971,852.11 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 143,229,061.63 | 290,357,789.64 | 276,604,798.53 | 180,520,381.64 |
| 减:所得税费用 | 20,920,933.99 | 55,949,057.24 | 21,824,884.3 | 16,529,599.43 |
| 六、净利润 | 122,308,127.64 | 234,408,732.4 | 254,779,914.23 | 163,990,782.21 |
| 持续经营净利润 | 122,308,127.64 | 234,408,732.4 | 254,779,914.23 | 163,990,782.21 |
| 归属于母公司股东的净利润 | 122,500,109.56 | 231,869,165.29 | 251,841,424.68 | 160,888,722.85 |
| 少数股东损益 | -191,981.92 | 2,539,567.11 | 2,938,489.55 | 3,102,059.36 |
| (一)基本每股收益 | 0.1 | 0.19 | 0.21 | 0.14 |
| (二)稀释每股收益 | 0.1 | 0.19 | 0.21 | 0.14 |
| 八、其他综合收益 | 7,874,799.08 | 17,401,641.1 | 11,364,521.71 | 14,178,611.73 |
| 归属于母公司股东的其他综合收益 | 7,874,799.08 | 17,401,641.1 | 11,364,521.71 | 14,178,611.73 |
| 九、综合收益总额 | 130,182,926.72 | 251,810,373.5 | 266,144,435.94 | 178,169,393.94 |
| 归属于母公司股东的综合收益总额 | 130,374,908.64 | 249,270,806.39 | 263,205,946.39 | 175,067,334.58 |
| 归属于少数股东的综合收益总额 | -191,981.92 | 2,539,567.11 | 2,938,489.55 | 3,102,059.36 |
| 公告日期 | 2024-04-25 | 2024-04-25 | 2023-10-26 | 2023-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |